Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Zealand and Roche's petrelintide has achieved good results at Phase II, showing 8-11% weight loss as well as lower side effects than approved incretin drugs.

expert reaction to trial of new amylin-based weight-loss drug petrelintide, noting fewer side effects than GLP-1-based drugs

Scientist comment on the trial of a new amylin-based weight-loss drug petrelintide, noting fewer side effects than GLP-1-based drugs, as published in The Lancet Diabetes & Endocrinology.   Dr Marie Spreckley, Research Programme Manager, Prevention of Diabetes and Related Metabolic Disorders in High Risk Groups, University of Cambridge, said: “In this trial, 485 people received at least one dose of petrelintide or placebo, and everyone received l…

Zealand and Roche's amylin works best at middle dose, trails Lilly's

MILAN — Weight loss with Zealand and Roche’s amylin analog was regarded as disappointing when its Phase 2 obesity trial reported topline data in March. Fuller data unveiled at a conference on Tuesday ...